Lisa A. Conte - 17 May 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Reporting relationship: CEO and President, Director
Issuer ticker: JAGX
Reported as of: 17 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2025, 17:00:07 UTC
Prior SEC filing: 02 Apr 2025
Next SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa A. Conte

Key filing fact

Lisa A. Conte filed Form 4 for Jaguar Health, Inc. (JAGX) on 20 May 2025.

Key facts

This page summarizes Lisa A. Conte's Form 4 filing for Jaguar Health, Inc. (JAGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 May 2025, 17:00.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001008377 Primary reporting owner

CONTE LISA A

Relationship: CEO and President, Director
Address: C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO
Signature: /s/ Lisa A. Conte
Signature date: 21 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +2
Change %: +0.3%
Price
Shares after: 666
Date: 17 May 2025
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JAGX transaction Derivative

Restricted stock units

Options Exercise

Transaction value: $0
Shares: -2
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 17 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2
Exercise price
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "May 2024 Reverse Stock Split). Upon effectiveness of the May 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 18, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "March 2025 Reverse Stock Split").

Footnote F3

(Continued from footnote 2) Upon effectiveness of the March 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

Footnote F4

The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split, May 2024 Reverse Stock Split and March 2025 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.